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10 Ambient intelligence (AmI) refers to environments in which
11 electronic devices work in concert to support people in their
12 everyday [1, 2] life activities, tasks, and rituals [3] in an
13 intuitive way. AmILCare (Ambient Intelligence for Long-
14 term diabetes Care) is a project aimed at developing
15 Information and Communication Technology solutions,
16 based upon an AmI paradigm and co-designed with
17 patients, to support healthy lifestyles in people with non
18 insulin-treated Type 2 Diabetes T2D [4]. BasedQ1Q2 upon an
19 integrated evaluation of the data collected by wearable
20 sensors, smart objects will communicate to patients whether
21 their daily activities have been more or less conducive to
22 maintaining a satisfactory metabolic control and preventing
23 complications. Feedbacks will take the form of emotional
24 messages (light, sound or cinematics effects, text/vocal
25 messages) from networked wearable devices or home
26 appliances [5].
27 In the first phase of AmILCare, we aimed at probing the
28 meaning that people with non-insulin-treated T2D attribute
29 to technology for self-care and their willingness to partici-
30 pate in co-designing AmI solutions.
31Research design and methods
32Thirty-four patients with non-insulin-treated T2D were
33recruited consecutively during their outpatient visits.
34Inclusion criteria were age <80, at least 1-year previous
35attendance in our clinic and treatment by lifestyle alone or
36with non-insulin anti-hyperglycaemic agents. Recruitment
37began in September 2019 and forcibly stopped at the end of
38January 2020, due to the COVID-19 pandemic.
39The study was in accordance with the 2013 Helsinki
40Declaration and approved by the Institutional Ethics Com-
41mittees of Città della Salute e della Scienza di Torino and
42Ordine Mauriziano di Torino. All patients signed an
43informed consent to participate.
44Socio-demographic and clinical variables
45Socio-demographic and clinical variables obtained within
46the previous 12 months are listed in Table 1. LDL Cho-
47lesterol and eGFR were calculated according to Q3Friedewald
48et al. [6] and Cockroft and Gault formula [7], respectively.
49Blood pressure was measured after 5 min lying using a
50mercury sphygmomanometer. Fundus examination was by
51digital retinal photography, graded according to Italian
52guidelines [8, 9]. None of the patients suffered from clini-
53cally evident coronary, peripheral, or cerebral vascular
54disease.
55Interview protocol and psychometric evaluation
56The patients were administered a 50 min structured inter-
57view, adapted from a tool to analyze the usability of tech-
58nology by adults [10]. The dimensions explored and the
59questions are listed in Table 2. Interviews were done by two
60researchers and transcribed verbatim. Analysis of the
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61 interviews included objective and quantitative descriptions
62 of the concepts expressed by the patients.
63 Quality of Life was measured using a 39-item DQoL/
64 Mod version adapted for patients with T2D, translated, and
65 revalidated into Italian [11]. The dimensions measured are:
66 the 14-item Satisfaction (14 items), impact of diabetes (20
67 items), and diabetes-relatedQ4 anxiety (5 items). Answers are
68 along 5-point Likert scales, from 1 (very satisfied) to 5 (very
69 dissatisfied). Scores range from 39 (best quality of life) to
70 195 (worst quality).
71 Self-esteem was measured by the Rosenberg Scale [12],
72 including ten items to be answered along 4-point Likert
73 scales. Scores ranges from 10 to 40, higher values corre-
74 sponding to better self-esteem.
75Statistical methods
76Data are shown as absolute and relative frequencies for
77categorical variables and as median and interquartile range
78for continuous variables. Distribution of answers to the
Table 1 Socio-demographic and clinical variables of the patients
interviewed
Sex M= 19; F= 15
Age 72 (63–73.50)
Schooling (primary school/middle school/
high school/university degree)
5/17/9/3
Occupation (retired/active in work) 13/21
Social status (living alone/married) 6/28
Smoking (never/currently/stopped) 13/6/15
Family history of DM (no/yes) 7/27




Anti-hyperthensive treatment (no/yes) 5/29
Group Care (no/yes) 23/11
Body weight (kg) 72 (65.5–84.5)
Body Mass Index (kg/m2) 27.5 (24.75–30)
Fasting blood glucose (mg/dl) 136.5 (126.25–159.5)
HbA1c (percent of total Hb) 7.05 (6.5–7.725)
HbA1c (mmol/mol) 51.5 (48–61)
Systolic blood pressure (mmHg) 138.5 (130–140.5)
Diastolic blood pressure (mmHg) 80 (70–80)
Total cholesterol (mg/dl) 160.5 (140.5–179.5)
HDL cholesterol (mg/dl) 41.5 (36–59)
LDL cholesterol (mg/dl) 82.9 (68.7–106.4)
Triglyceride (mg/dl) 116.5 (94–150)
Creatinine (mg/dl) 0.775 (0.6375–0.9875)
ACR 0.95 (0.2375–2.03)




Foot lesions (none) 34
Absolute frequencies are used for categorical variables and medians
and IQ range for continuous variables
Table 2 Dimensions, questions and answers to the protocol interview
N (%)
(a) Interest in technology: “There is a growing interest
in technologies that can be used to help people support
healthy lives. What do you think?”
Not interested 3 (8.8)
Interested 31 (91.2)
(b) Use and interest in technology in connection to
personal health: “Do you use technologies to stay
healthy?”
No use 9 (26.5)
Use for blood sugar control 1 (2.9)
Use for blood pressure control 15 (44.1)
Use for both 9 (26.5)
(c) Personal motivation: “Why do you use these
technologies?”
Don’t know 2 (5.9)
Personal safety 6 (17.6)
To check health 22 (64.7)
Both previous items 4 (11.8)
(d) Preferences for sharing health information:




Both previous items 5 (14.7)
(e) Support and Help: “What would you like to be
included in these devices to help manage your diabetes?”
None 5 (14.7)
To help control nutrition 21 (61.8)
To help control diabetes 3 (8.8)
To avoid pain 5 (14.7)
(f) Design: “What should the features of the device be?”
None 6 (17.6)
Small and discreet object 16 (47.1)
Nonintrusive object 7 (20.6)
Both previous items 5 (14.7)
(g) Design: “Would you like to design the device?”
No 27 (79.4)
Yes 7 (20.6)
(h) Intention to participate in co-designing technology:
“Would you be interested in interacting with those who
design technology to guide the design process of products




79 protocol interview were compared by gender by means of a
80 chi-square test.
81 Results
82 Although we had planned to recruit 50 subjects, the
83 COVID-19 pandemic forced us to stop at 34 interviews.
84 The patients had a median age of 72 years and 16.5 years
85 disease duration (Table 1).
86 DQoL Total (M= 64.5—IQ: 60.75–73.75), and its
87 dimensions Satisfaction (M= 29—IQ: 26–32), impact
88 (M= 27.5—IQ: 24–33.25), and worry (M= 8—IQ:
89 6–10.25) suggested good quality of life, similarly to self-
90 esteem scores (M= 34.5—IQ: 30–37.25).
91 Table 2 shows the distribution of answers to the inter-
92 views.Q5 Nearly all persons showed interest in the AmI pro-
93 ject, and technology had a positive connotation to them.
94 Personal motivation to use technology included checking
95 health, personal safety, or both. Except for three patients,
96 most wished to share personal health information with their
97 physician or family.
98 There were no gender differences in the propensity to use
99 technology for health control, personal motivation, whom to
100 share health information with or support in disease care.
101 Regarding the characteristics of technology aids, women
102 favored small discreet objects, men valued non-
103 intrusiveness (p= 0.05). Women were more inclined to
104 draft an object for the AmILcare project (p= 0.10).
105 Patients aiming to monitor their health and wishing to
106 share information with family showed trends to better
107 scores on the quality of life scale for complications; lower
108 HbA1c scores were recorded among those interested in the
109 construction of new devices.
110 Discussion
111 Integrating technology into health care shifts accountability
112 from professionals to patients, redefining their role from
113 passive recipients to active participants and requiring that
114 they acquire specific competences [13], a main problem for
115 non-technologically literate people. AmI aims at providing
116 nonintrusive, intuitive solutions to make technology easily
117 available to people. A key point of AmILCareQ6 is the
118 involvement of patients with diabetes in co-designing smart
119 objects that will support them in their daily choices to
120 maintain good control [14]. This study aimed at exploring
121 how people with T2D perceive technology, whether they
122 use it in daily life, and their willingness to participate in
123 developing solutions they might benefit from. Since self-
124 management involves daily choices made without the sup-
125 port of operators, people with T2D need support that is
126simple and easy to use. AmILCare aims at developing smart
127objects that will collect and process data about patients’
128behaviors and clinical variables and provide them with
129feedbacks to improve control.
130The interviews revealed the willingness of patients to
131participate in the project and some of their preferences. As
132shown in Table 2, they wish to control blood pressure,
133presumably because they experience this noninvasive
134manouvre during medical examinations [15], and prefer to
135discuss their health problems with their doctor, as in our
136clinic they spend more time talking with physicians than
137other professionals [16]. In terms of benefits expected of an
138AmI environment, women preferred to receive advice on
139nutrition but did not ask for specific information. As eating
140behaviors may change over time, choices need to be
141adapted accordingly [17].
142The request for small, nonintrusive objects is in line with
143the AmI paradigm [18], stating that technology should be
144supportive and respect expectations without becoming
145intrusive. Co-production of technology is a complex pro-
146cess, empowering and at the same time exploiting actors. It
147needs theoretical tools [18, 19] as a user’s perception is
148affected by a continuum from expectations to experience
149with a given service [19]. Our interviews showed a pro-
150pensity by women to get involved in co-design, a useful
151aspect to nurture support in managing the disease [20].
152Opportunities for training and involvement enable patients
153to personally acknowledge the challenges inherent in
154treating diabetes, a perspective that helps establish them as
155partners in decision-making [20]. This is, to our knowledge,
156the first study to inquire directly about the attitudes of
157people with non insulin-treated T2D towards health care
158technology, with a specific insight into AmI solutions. A
159limitation is the small number of patients. Unfortunately,
160the outbreak of the Covid-19 pandemic made it unsafe to
161continue summoning patients for interviews in presence.
162However, the interviews helped reveal interests and
163expectations and gave indications about the characteristics
164that smart objects should have to make them acceptable and
165usable. This approach could be extended to other inter-
166ventions aimed at promoting patient participation and wish
167to collaborate in decision-making and disease self-
168management.
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